Anticancer effects of O-desmethylangolensin are mediated through  cell cycle arrest at the G2/M phase and mitochondrial-dependent apoptosis in Hep3B human hepatocellular carcinoma cells

Choi,Eun  Jeong; Lee,Jae-In; Kim,Gun-Hee

doi:10.3892/ijmm.2013.1230

Anticancer effects of O-desmethylangolensin are mediated through cell cycle arrest at the G2/M phase and mitochondrial-dependent apoptosis in Hep3B human hepatocellular carcinoma cells

Authors:
- Eun Jeong Choi
- Jae-In Lee
- Gun-Hee Kim
View Affiliations

Affiliations: Plant Resources Research Institute, Duksung Women's University, Tobong-ku, Seoul 132-714, Republic of Korea
Published online on: January 8, 2013 https://doi.org/10.3892/ijmm.2013.1230
Pages: 726-730

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, in order to investigate the anticancer effects of O-desmethylangolensin (O-DMA) on human hepatocellular carcinoma Hep3B cells, we first examined the antiproliferative effect of O-DMA. When Hep3B cells were treated with O-DMA at various concentrations (5-200 µM) for 24, 48 or 72 h, cell proliferation decreased significantly in a dose- and time-dependent manner. Moreover, O-DMA exposure at the IC50 concentration for 72 h arrested cells at the G2/M phase, which was accompanied by a reduction in CDK1, and an increase in cyclin A and B. Under the same conditions, O-DMA significantly increased the number of sub-G1 phase cells. Additionally, an Annexin V assay revealed that exposure to O-DMA affected the rate of cell apoptosis. O-DMA caused the downregulation of Bcl-2 and upregulation of Bax, which led to cytochrome c release from the mitochondria and activation of caspase-3. Taken together, these data suggest that O-DMA exhibits anticancer activity by arresting the cell cycle at G2/M phase and causing mitochondrial-dependent apoptosis in Hep3B cells.

View Figures

View References

1	L’homme R, Brouwers E, Al-Maharik N, Lapcík O, Hampl R, Mikola H, Wähälä K and Adlercreutz H: Time-resolved fluoroimmunoassay of plasma and urine O-desmethylangolensin. J Steroid Biochem Mol Biol. 81:353–361. 2002.
2	Heinonen S, Wähälä K and Adlercreutz H: Identification of isoflavone metabolites dihydrodaidzein, dihydrogenistein, 6’-OH-O-dma, and cis-4-OH-equol in human urine by gas chromatography-mass spectroscopy using authentic reference compounds. Anal Biochem. 274:211–219. 1999.PubMed/NCBI
3	Hwang J, Wang J, Morazzoni P, Hodis HN and Sevanian A: The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Radic Biol Med. 34:1271–1282. 2003. View Article : Google Scholar : PubMed/NCBI
4	Turner R, Baron T, Wolffram S, Minihane AM, Cassidy A, Rimbach G and Weinberg PD: Effect of circulating forms of soy isoflavones on the oxidation of low density lipoprotein. Free Radic Res. 38:209–216. 2004. View Article : Google Scholar : PubMed/NCBI
5	Rüfer CE and Kulling SE: Antioxidant activity of isoflavones and their major metabolites using different in vitro assays. J Agric Food Chem. 54:2926–2931. 2006.PubMed/NCBI
6	Choi EJ and Kim GH: Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine. 15:683–690. 2008. View Article : Google Scholar : PubMed/NCBI
7	Jin S, Zhang QY, Kang XM, Wang JX and Zhao WH: Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway. Ann Oncol. 21:263–268. 2010. View Article : Google Scholar : PubMed/NCBI
8	Green JM, Alvero AB, Kohen F and Mor G: 7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: a novel compound capable of inducing cell death in epithelial ovarian cancer stem cells. Cancer Biol Ther. 8:1747–1753. 2009. View Article : Google Scholar : PubMed/NCBI
9	Gercel-Taylor C, Feitelson AK and Taylor DD: Inhibitory effect of genistein and daidzein on ovarian cancer cell growth. Anticancer Res. 24:795–800. 2004.PubMed/NCBI
10	Rabiau N, Kossaï M, Braud M, Chalabi N, Satih S, Bignon YJ and Bernard-Gallon DJ: Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. Cancer Epidemiol. 34:200–206. 2010. View Article : Google Scholar : PubMed/NCBI
11	Su SJ, Chow NH, Kung ML, Hung TC and Chang KL: Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity. Nutr Cancer. 45:113–123. 2003. View Article : Google Scholar : PubMed/NCBI
12	Borradaile NM, de Dreu LE, Wilcox LJ, Edwards JY and Huff MW: Soya phytoestrogens, genistein and daidzein, decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms. Biochem J. 366:531–539. 2002. View Article : Google Scholar : PubMed/NCBI
13	Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME and Wang G: Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 53:6153–6163. 2010. View Article : Google Scholar : PubMed/NCBI
14	Singh-Gupta V, Zhang H, Yunker CK, Ahmad Z, Zwier D, Sarkar FH and Hillman GG: Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy. Pharm Res. 27:1115–1127. 2010. View Article : Google Scholar : PubMed/NCBI
15	Guo JM, Xiao BX, Dai DJ, Liu Q and Ma HH: Effects of daidzein on estrogen-receptor-positive and -negative pancreatic cancer cells in vitro. World J Gastroenterol. 10:860–863. 2004.PubMed/NCBI
16	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
17	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
18	Schmitt E, Dekant W and Stopper H: Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro. 15:433–439. 2001. View Article : Google Scholar : PubMed/NCBI
19	Guo JM, Xiao BX, Liu DH, Grant M, Zhang S, Lai YF, Guo YB and Liu Q: Biphasic effect of daidzein on cell growth of human colon cancer cells. Food Chem Toxicol. 42:1641–1646. 2004. View Article : Google Scholar : PubMed/NCBI
20	Magee PJ and Rowland IR: Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr. 91:513–531. 2004. View Article : Google Scholar : PubMed/NCBI
21	Gogel WC and Tietz JD: Absence of compensation and reasoning-like processes in the perception of orientation in depth. Percept Psychophys. 51:309–318. 1992. View Article : Google Scholar : PubMed/NCBI
22	Bingham SA, Atkinson C, Liggins J, Bluck L and Coward A: Phyto-oestrogens: where are we now? Br J Nutr. 79:393–406. 1998. View Article : Google Scholar : PubMed/NCBI
23	Tang BY and Adams NR: Effect of equol on oestrogen receptors and on synthesis of DNA and protein in the immature rat uterus. J Endocrinol. 85:291–297. 1980. View Article : Google Scholar : PubMed/NCBI
24	Shutt DA and Cox RI: Steroid and phyto-oestrogen binding to sheep uterine receptors in vitro. J Endocrinol. 52:299–310. 1972. View Article : Google Scholar : PubMed/NCBI
25	Pfitscher A, Reiter E and Jungbauer A: Receptor binding and transactivation activities of red clover isoflavones and their metabolites. J Steroid Biochem Mol Biol. 112:87–94. 2008. View Article : Google Scholar : PubMed/NCBI
26	Shackelford RE, Kaufmann WK and Paules RS: Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med. 28:1387–1404. 2000.PubMed/NCBI
27	Hunter T and Cooper JA: Protein-tyrosine kinases. Annu Rev Biochem. 54:897–930. 1985. View Article : Google Scholar
28	Collins I and Garrett MD: Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 5:366–373. 2005. View Article : Google Scholar : PubMed/NCBI
29	Sandhu C and Slingerland J: Deregulation of the cell cycle in cancer. Cancer Detect Prev. 24:107–118. 2000.PubMed/NCBI
30	Chi TY, Chen GG and Lai PB: Eicosapentaenoic acid induces Fas-mediated apoptosis through a p53-dependent pathway in hepatoma cells. Cancer J. 10:190–200. 2004. View Article : Google Scholar : PubMed/NCBI
31	Murakami Y, Hayashi K, Hirohashi S and Sekiya T: Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:5520–5525. 1991.PubMed/NCBI
32	Oakes SA, Lin SS and Bassik MC: The control of endoplasmic reticulum-initiated apoptosis by the BCL-2 family of proteins. Curr Mol Med. 6:99–109. 2006. View Article : Google Scholar : PubMed/NCBI
33	van Delft MF and Huang DC: How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 16:203–213. 2006.PubMed/NCBI
34	Alonso V, Pérez-Martínez FC, Calahorra FJ and Esbrit P: Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells. Life Sci. 85:421–430. 2009. View Article : Google Scholar : PubMed/NCBI
35	Alhasan SA, Ensley JF and Sarkar FH: Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int J Oncol. 16:333–338. 2000.PubMed/NCBI
36	Jiang X and Wang X: Cytochrome C-mediated apoptosis. Annu Rev Biochem. 73:87–106. 2004. View Article : Google Scholar
37	Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar : PubMed/NCBI
38	Abu-Qare AW and Abou-Donia MB: Biomarkers of apoptosis: release of cytochrome c, activation of caspase-3, induction of 8-hydroxy-2’-deoxyguanosine, increased 3-nitrotyrosine, and alteration of p53 gene. J Toxicol Environ Health B Crit Rev. 4:313–332. 2004.PubMed/NCBI